Interestingly, SDF‐1 has been previously implicated in immunosuppression and tumor progression in PDAC (Feig et al, 2013) and downregulation of SDF‐1 may contribute to the therapeutic effect of RT + anti‐PD‐L1 in reversing the immunosuppressive phenotype. This evidence concerns the gene CXCL12 and neoplasm.